Porsolt & Metris Sign a Co-Marketing Agreement
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Porsolt and Partners Pharmacology (Porsolt) and Metris have announced that they have entered into a global co-marketing agreement to promote preclinical screening services using Laboras , a non-invasive technology for automatic and comprehensive in vivo behavioral characterization of drug candidates.
Under this alliance, Porsolt will offer CRO services utilizing the in vivo screening platform to its clients. The Laboras system enables the measurement of multiple behavioral pharmacodynamic endpoints in a single experiment utilizing a high throughput non-invasive system.
Dr. Martine Lemaire, Senior Director - Commercial & Business Development of Porsolt said, “We are thrilled by the synergy between Porsolt’s long-established and recognized expertise in behavioral pharmacology and the high-quality, proven utility of the Laboras innovative technology system.
This partnership has formed in response to the needs expressed by Porsolt’s clients for increased information on drug-like molecules earlier in the drug discovery process. It fits obviously with our strategy to constantly deliver superior quality scientific solutions tailored to our customer’s need.”
Under this alliance, Porsolt will offer CRO services utilizing the in vivo screening platform to its clients. The Laboras system enables the measurement of multiple behavioral pharmacodynamic endpoints in a single experiment utilizing a high throughput non-invasive system.
Dr. Martine Lemaire, Senior Director - Commercial & Business Development of Porsolt said, “We are thrilled by the synergy between Porsolt’s long-established and recognized expertise in behavioral pharmacology and the high-quality, proven utility of the Laboras innovative technology system.
This partnership has formed in response to the needs expressed by Porsolt’s clients for increased information on drug-like molecules earlier in the drug discovery process. It fits obviously with our strategy to constantly deliver superior quality scientific solutions tailored to our customer’s need.”
